PUBLIC COMPANY
saveKite Pharma Inc
updated 3mo ago
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 2
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →🐶 Hiring Signal
News
- Milestone cutting 20% of HQ team, including CMOFollow along as BioSpace tracks job cuts and restructuring initiatives.biospace · 20h ago
- Cellectis will shed 70% of workforce as part of in vivo pivotCellectis’ pivot from allogeneic CAR-Ts to in vivo therapies is set to come at the expense of 70% of its workforce.fiercebiotech · 1d ago
- Gilead reveals partial clinical hold on 2 CAR-T cell therapy trialsGilead Sciences announced on its third-quarter earnings call Oct. 29 that the company has placed a partial clinical hold on two studies for the CAR-T cell therapy KITE-753 in diffuse large B-cell l…fiercebiotech · 15d ago
- Parkinson’s-focused Aspen and bispecific biotech Bambusa both shoot for $134M IPOsParkinson’s disease cell therapy-focused Aspen Neuroscience and bispecific biotech Bambusa Therapeutics are each hoping to raise around $134 million from their respective IPOs.fiercebiotech · 18d ago
- Parkinson’s-focused Aspen and bispecific biotech Bambusa plan IPOsParkinson’s disease cell therapy-focused Aspen Neuroscience and bispecific biotech Bambusa Therapeutics are the latest drug developers to eye up a public listing.fiercebiotech · 1mo ago
- CAR-T biotech Caribou makes ‘heartbreaking’ call to shrink headcount, halt pipelineThe Bay Area biotech is discontinuing all clinical development activities and implementing a "substantial reduction in workforce."fiercebiotech · 1mo ago
- BioSpace 40 Under 40 winners make their mark on biopharma40 Under 40 honorees’ accomplishments include co-developing the world’s first synthetic biology programming language for mRNA and co-founding and leading a company acquired for $700 million up-fron…biospace · 1mo ago
- Cellectis cans allogeneic CAR-Ts to hop aboard in vivo bandwagonCellectis may have kicked off the year promising “huge momentum” in the allogeneic CAR-T space, but even the French biotech has been unable to resist the dominance of in vivo options.fiercebiotech · 2mo ago
- CEO O’Day tells Fierce how Gilead’s cancer, inflammation expansion has reached ‘critical mass’Following a steady stream of acquisitions that culminated in three biotech buyouts earlier this year, Gilead has now reached “critical mass” in its efforts to diversify into oncology and inflammati…fiercebiotech · 2mo ago
- ArsenalBio sheds most of staff in pivot to in vivo CAR-TAbout a year after halving its staff in a clinical push, Arsenal Biosciences is now making a hard pivot that involves laying off most of its employees and seeking out new homes for its assets.fiercebiotech · 2mo ago
comments(0)
5-min edit window · permanent after that